



**Commercial PA Criteria**  
**Effective: October 13, 2023**

**Prior Authorization:** Lodoco (colchicine)

**Products Affected:** Lodoco (colchicine) oral tablets

**Medication Description:** Lodoco, an alkaloid, is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular (CV) death in adults with established atherosclerotic disease or with multiple risk factors for CV disease.

**Covered Uses:** *Atherosclerotic occlusive disease, Established, or multiple risk factors for cardiovascular disease; reduce risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death*

**Exclusion Criteria:**

1. Primary prevention of cardiovascular disease
2. Concomitant use of P-glycoprotein and strong CYP3A4 inhibitors in patients with renal or hepatic impairment
3. Patients with both renal and hepatic impairment
4. Patients with preexisting blood dyscrasias
5. Hypersensitivity to colchicine or any component of the product (tablet)

**Required Medical Information:**

1. Diagnosis
2. Medical History
3. Current laboratory values

**Prescriber Restriction:** Medication must be prescribed by, or in consultation with, a cardiologist or Internal medicine /Primary care prescriber

**Age Restriction:** 18 years and older

**Coverage Duration:** 12 months

**Other Criteria:**

**Initial Approval Criteria**

1. **Atherosclerotic Disease.** Approve if the patient meets the following (A, B, C, **AND** D ):
  - A. Patient has had one of the following conditions or diagnoses (i, ii, iii, iv, v, **OR** vi):
    - i. A previous myocardial infarction or a history of an acute coronary syndrome; **OR**
    - ii. Angina (stable or unstable); **OR**
    - iii. A past history of stroke or transient ischemic attack; **OR**

October 2023



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

- iv. Coronary artery disease; **OR**
- v. Peripheral arterial disease; **OR**
- vi. Patient has undergone a coronary or other arterial revascularization procedure in the past; **AND**  
*Note: Examples include coronary artery bypass graft surgery, percutaneous coronary intervention, angioplasty, and coronary stent procedures.*

B. Lodoco is being added onto other background regimens of other atherosclerotic disease medications according to the prescriber; **AND**

*Note: Examples of medications recommended in guideline-directed therapy for patients with atherosclerotic disease can include aspirin, antiplatelet agents (e.g., clopidogrel, Brilinta [ticagrelor tablets]), anticoagulants, lipid-lowering agents (e.g., statins such as atorvastatin and rosuvastatin), beta blockers, angiotensin-converting enzyme inhibitors, and/or angiotensin receptor blockers.*

- C. Patient does not have severe hepatic impairment according to the prescriber; **AND**
- D. Patient has a creatinine clearance  $\geq$  50 mL/min.

**References:**

1. Lodoco® tablets [prescribing information]. Parsippany, NJ: Agepha; June 2023.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	10/13/2023

